Topic Listing for Vaxart, Inc.

Accounts Receivable Revenue Recognition Accrued Expenses
Accrued Expenses Other Current Liabilities Acknowledgment Commencement Date
Additional Audit Information Additional Outlook 2005
Additional Product Filings Administration
Adoption Fin Adoption New Accounting Guidance Transition
Advancing Strategic Initiatives Advises Stockholders Take Action Time
Aggregated Option Exercises Last Year-end Values Agreement
Agreements Aloprim Allopurinol Sodium Injection
Altastaph Altastaph Next Generation
Altastaph Staphylococcus Aureus Immune Globulin Intravenous Human Amended 2005
Amendment Amendment Asset Purchase Agreement
Amendment Rights Agreement Amendment Termination Espp
Among Amortization Intangible Assets Expense 2006 Compared 2005
Amortization Intangible Assets Expense Was 2006 Compared 2005 Annex Exhibits
Annual Cash Incentive Compensation Annual Equity Awards
Annual Report Form 10-k Anti-d Polyclonal Antibody
Anti-nicotine Antibody Levels Drive Long-term Smoking Abstinence Anti-takeover Provisions Charter Documents Delaware Law Stockholder Rights
Antibody Collection Process Antibody Products
Antibody Revenues Antibody Sales
Appointment Chief Executive Officer Appointment Geoffrey Cox Phd Non-executive Chairman Board Directors
Appointment Interim Chief Executive Officer Appointment Leslie Hudson Phd Interim Chief Executive Officer
Approval Proposals Contained Herein Asset Purchase Agreement
Asset Purchase Agreement Continuing Obligations Indemnify Biotest Subject Assignment
Assumption Liabilities Atg-fresenius Anti-thymoglobulin
Atg-fresenius North America Attendance Annual Meetings Stockholders
Audit Audit Committee Charter
Audit Committee Report Aureus Infection Rates Patient Populations High Risk Infections
Available Information Background
Background Statement Base Salary
Basis Presentation Summary Significant Accounting Policies Beneficial Ownership Reporting Compliance
Benefits Perquisites Between
Bingham Mccutchen Llp Biologics Strategic Business Unit Asset Purchase Agreement Continuing
Biopharmaceutical Products Biopharmaceutical Sales
Biotest Biotest Claim
Biotest Claims Bla License Application Nabi-hb Intravenous Not Approved
Bla License Application Nabi-hb Intravenous Not Approved Competitive Board Composition Matters Nominations 2007 Stockholder Meeting
Board Directors Board Directors Recommends Vote Proposal Approve Amendment Restatement
Board Self-assessment Bob Wasserman Dawson James
Boca Raton Florida 33487 Business Organization
Buyer Transition Assistance Buyers Agreement Indemnify
Call Webcast Information Cambrex Bio Science Baltimore Inc
Capital Changes Cash Awards
Cash Flow Operating Activities Cash Incentive Compensation
Cash Incentive Plan Compensation Cautionary Statement Regarding Forward-looking Statements
Certain Relationships Related Transactions Certain Relationships Related Transactions Director Independence
Certification Certifications
Change Control Agreements Change Control Severance Agreement
Change Control Severance Agreements Employment Change Orders
Changes Disagreements Accountants Accounting Financial Disclosure Changes Internal Control Over Financial Reporting
Chiron Corporation Choice Law Jurisdiction
Cigarette Smoking Growing Global Health Challenge Civacir
Civacir Hepatitis Immune Globulin Human Claims Concerns Arise Regarding Safety Efficacy Product Candidates
Claims Concerns Arise Regarding Safety Marketed Products Lead Clinical Regulatory History
Clinical Trial History Clinical Update Provided Nicvax Phase Proof Concept Trial
Closing Closing Conditions
Code Ethical Conduct Commitments Contingencies
Common Stock Available Awards Plan Common Stock Par Value Per Share
Comparative Stock Performance Compared 2003
Compared 2004 Compared 2005
Compared 2006 Compared 2007
Compensation Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Discussion Analysis
Compensation Objectives Philosophy Compensatory Arrangements Certain Officers
Compete Larger Better-financed Mature Pharmaceutical Biotechnology Companies Capable Competition
Completion Acquisition Disposition Assets Compliance Government Regulations
Condensed Consolidated Balance Sheets Condensed Consolidated Statements Operations
Conditions Closing Conference Call
Conference Call Webcast Information Confidential Information Legal Proceedings
Confidential Information Trading Seller Securities Confidential Portion Material Been Omitted Filed Separately Securities
Confidentiality Confidentiality Public Announcements
Connection Sale Biologics Business Certain Corporate Shared Services Consent Independent Registered Public Accounting Firm
Consideration Construction
Contemplated Transactions Continuing Obligations Indemnify Biotest Biologics Strategic Business Unit
Continuous Long-term Smoking Abstinence Contract Manufacturing
Contract Manufacturing Other Services Controls Procedures
Conversion 2875 Convertible Senior Notes Dilute Ownership Interest Conversion Notes Dilute Ownership Interest Existing Stockholders
Convertible Senior Notes Convertible Senior Notes Due 2025
Corporate Governance Principles Corporate Governance Principles Majority Vote Election Directors Policy
Corporate Shared Services Costs Associated Exit Disposal Activities
Creation Material Financial Obligation Credit Facilities
Credit Facility Critical Accounting Policies
Critical Accounting Policies Estimates Currency Exchange Rate Fluctuations Adversely Affect Results Operations
Current Healthcare Laws Future Legislative Changes System Affect Customer Relationships
Data Presented Today American Heart Association Scientific Sessions David Braille Para
Deal Expected Close 2007 Debt
Default Definitions
Definitions Interpretation Definitions References
Department Defense Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Principal Officers Election Appointment Departure Directors Principal Officers Election Appointment Compensatory
Depend Parties Manufacture Biopharmaceutical Products Depend Parties Manufacture Certain Biopharmaceutical Products Subject Milestone
Depend Parties Manufacture Products Development Description Base Building
Description Plan-based Awards Description Premises
Description Project Description Services
Develop Supply Market Atg Fresenius North America Development
Development Progress Date Director Compensation
Director Election Paid Annual Cash Retainer Shares Director Nomination Process
Director Nominees Directors Executive Officers Corporate Governance
Directors Executive Officers Registrant Disaster Sole Manufacturing Site Interrupt Capability Products Produced
Disaster Sole Manufacturing Sites Interrupt Capability Products Produced Disclosure Controls Procedures
Dispute Resolution Distribution Agreement
Dividends Dividend Equivalents Documents Incorporated Reference
Drawing Lot Line Adjustment Earnings Per Share
Effect Certain Corporate Events Effect Expiration Termination
Effect Merger Consolidation Sale Transfer Effective 2004
Effective 2007 Election Directors
Eligibility Employee Benefit Plans
Employee Matters Employee Stock Plan
Employee Stock Purchase Plan Employee Stock Purchase Plan Espp
Employees Employment Agreement
Employment Agreement Leslie Hudson Phd Interim President Chief Employment Agreements
Enter Strategic Alliances Not Successful Adversely Affect Ability Entered Continue Enter Strategic Alliances Not Successful Adversely
Entry Definitive Material Agreement Entry Material Definitive Agreement
Equity Compensation Plan Information Equity Incentive Compensation
Equity-based Compensation Espp
Exact Name Registrant Specified Charter Except Per Share Amounts
Exchange Act 1934 Exchange Act 1934 Amendment
Executive Compensation Executive Officers Registrant
Exhibits Expansion Projects
Expected Dividend Yield Not Intend Pay Dividends Common Fail Comply Extensive Regulations Enforced Fda Emea Paul
Fail Comply Extensive Regulations Enforced Fda Foreign Regulatory Fail Comply Reporting Payment Obligations Medicaid Rebate Program
Failure Close Biologics Sbu Sale Biotest Material Adverse Fair Value Disclosures
Fast Track Designation Fast Track Status
Federal Income Tax Consequences Incentive Compensation Fifth Amendment Rights Agreement
Financial Information Segments Geographic Areas Financial Results
Financial Results Conference Call Financial Results Conference Call Webcast Information
Financial Statements Financial Statements Exhibits
Force Majeure Form 10-k
Form 10-q Form 8-k
Former Name Address Changed Since Last Report Forward Looking Statements
Forward-looking Statement Forward-looking Statements
Fresenius Fresenius Biotech
Full-year Net Loss Continuing Operations Declines Cash Used General Provisions Applicable Awards
Government Industry Regulation Gram-positive Antibody Products
Gram-positive Program Gram-positive Vaccines
Grant Rights Grants Plan-based Awards
Gregor Schultz- Biotest Ag-chairman Management Board Headings Sections Subsections Agreement Inserted Convenience Only Shall
Heightened Concerns Over Antibody Products Screening Measures Adversely Held 2005
Held 2006 Held 2007
Held 2008 Held 2009
Hematology Oncology Host Conference Call Today 430 Edt
Http Phxcorporate-irnet Phoenixzhtmlpirol-eventdetailsc100445eventid1641393 Http Phxcorporate-irnet Phoenixzhtmlpirol-eventdetailsc100445eventid1673091
Http Phxcorporate-irnet Phoenixzhtmlpirol-eventdetailsc100445eventid2109473 Http Phxcorporate-irnet Phoenixzhtmlpirol-eventdetailsc100445eventid2195269
Http Phxcorporate-irnet Phoenixzhtmlpirol-eventdetailsc100445eventid2332831 Immediate Release
Important Additional Information Filed Sec Important Information
Important Information Investors Stockholders Improved Financial Performance Continues Stockholders Approve Sale Nabi
Inability Enter Strategic Alliances Allow Successfully Develop Manufacture Inability Enter Successfully Manage Strategic Relationships Develop Manufacture
Incentive Stock Plan Income Taxes
Increase Focus Other Pipeline Products Increase Supply Decrease Demand Antibody Products Materially Adversely
Indemnification Indemnification Insurance
Indemnification Limitation Liability Independent Contractor
Independent Registered Public Accounting Firm Index
Index Exhibits Infectious Disease
Initial Phase Clinical Trial Staphvax Did Not Achieve Initial Principal Amount Global Security 000
Insurance Intangible Assets
Intangible Assets Manufacturing Right Intangible Assets Phoslo Intangibles
Integration Effect Amendment Intellectual Property
Interest Income Was 2009 2008 Respectively Earned Cash Intravenous Immune Globulin Ivig Other Plasma-based Proteins
Intravenous Immune Globulin Ivig Plasma-based Proteins Inventions Patents Technology Transfer
Inventories Inventories Net
Inventory Reserves Slow Moving Obsolete Jalaa Equities
Kathy Reese Analyst Kedrion Spa
Keri Mattox- Nabi Biopharmaceuticals Kevin Gale- Radcliffe Group-analyst
Key Financing Activities Key Operating Activities
Leadership Leases
Legal Description Land Legal Proceedings
Licenses Grants Rights Licenses Royalty Agreements
Limitation Liability Liquidity Capital Resources
Litigation Loss Per Share
Management Related Stockholder Matters Managements Annual Report Internal Control Over Financial Reporting
Manufacture Licensed Product Manufacture Supply
Manufacturing Services Agreement Market Not Receptive Products Introduction
Market Registrants Common Equity Related Stockholder Matters Issuer Market Risk
Market Value Underlying Securities 2007 Omnibus Incentive Plan Marketed Products
Massachusetts Florida Common Law Other Federal State Local Material Impairments
Medicare Medicaid Contingencies Medicare Prescription Drug Improvement Modernization Act Reimbursement
Milestone Definitions Milestone Update
Milestones Milestones Achieved
Milestones Royalties Miscellaneous
Miscellaneous Provisions Mutual Cooperation
Nabi Nabi Biologics
Nabi Biologics Sale Completed Undergo Significant Changes Face Nabi Biopharmaceuticals
Nabi Biopharmaceuticals Announces 2007 Financial Results Nabi Biopharmaceuticals Announces 2007 Financial Results Positive Vote
Nabi Biopharmaceuticals Announces 2008 Financial Results Nabi Biopharmaceuticals Announces 2009 Financial Results
Nabi Biopharmaceuticals Announces Full-year 2008 Financial Results Nabi Biopharmaceuticals Announces Positive Results Phase Iib Trial
Nabi Biopharmaceuticals Announces Resignation Thomas Mclain Ceo Appointment Nabi Biopharmaceuticals Announces Sale Biologics Biotest
Nabi Biopharmaceuticals Board Authorizes Exploration Strategic Alternatives Further Nabi Biopharmaceuticals Files Form 10-k Corrects Financial Tables
Nabi Biopharmaceuticals Proposed Asset Sale Nabi Biopharmaceuticals Sent Letter Below Employees 2006
Nabi Biopharmaceuticals Signs Definitive Agreement Sell Phoslo Fresenius Nabi Biopharmaceuticals Updates European Commercialization Strategy
Nabi Pharmaceuticals Nabi Proxy Statement Sec Connection Proposed Transaction Urges
Nabi Savings Retirement Plan Nabi-hb Hepatitis Immune Globulin Human
Nabi-hb Intravenous Hepatitis Immune Globulin Human Nabi-hb Revenues
Name Person Filing Proxy Statement Other Registrant Named Executive Officer Base Salaries
Names National Institute Allergy Infectious Diseases
National Institute Drug Abuse National Institutes Health
New Accounting Pronouncements New Plan Benefits
New Treatments Reduce Demand Antibodies Antibody Based Biopharmaceutical New Treatments Reduce Demand Antibodies Antibody-based Biopharmaceutical Products
News Release Next Generation Products Other Anti-bacterial Vaccines Development
Next Steps Nicotine Addiction
Nicvax Nicvax Designed Work
Nicvax Development Progress Date Nicvax Nicotine Conjugate Vaccine
Nicvax Nine-month Data Key Findings Nicvax Phase Clinical Trial Update
Non-competition Buyer Non-qualified Employee Stock Option Plan
Non-reliance Previously Issued Financial Statements Related Audit Non-specific Antibodies
Noncompetition Nonsolicitation Agreement Not Ability Raise Funds Necessary Repay Convertible Senior
Not Able Advance Gram-positive Infections Program Without Obtaining Not Able Develop Commercialize New Biopharmaceutical Products Successfully
Not Able Maintain Sufficient Insurance Including Products Liability Not Able Maintain Sufficient Product Liability Directors Officers
Not Able Maintain Sufficient Property Insurance Facilities Florida Not Able Raise Necessary Additional Capital Acceptable Terms
Not Able Renew Leases Rockville Maryland Facilities Acceptable Not Able Successfully Commercialize Gram-positive Infections Products Development
Not Collect Further Milestone Royalty Payments Phoslo Agreement Not Continue Commercialize Able Successfully Gram-positive Infections Products
Not Currently Able Utilize Full Capacity Boca Raton Not Currently Able Utilize Full Capacity Plasma Fractionation
Not Generate Sufficient Cash Flow Biopharmaceutical Antibody Products Not Realize Value Acquisition Phoslo
Not Realize Value Acquisition Phoslo Effectively Nephrology Sales Not Successful Licensing Operating Internal Commercial Scale Vaccine
Not Successful Licensing Operating Vaccine Manufacturing Plant Not Sufficient Capital Resources Fully Develop Commercialize Market
Not Sufficient Capital Resources Fully Develop Commercialize Products Notes Consolidated Financial Statements
Notes Pro Forma Condensed Consolidated Financial Statements Notice
Novartis Number 000-04829
Number Gender Number Product Candidates Marketed Products Development Undergo Clinical
Number Product Candidates Products Development Undergo Clinical Trials Offering Periods
Offering Registrations Omnibus Equity Incentive Plan
Operating Expenses Operating Income Loss Segment Follows
Opinion Nabi Biopharmaceuticals Maintained Material Respects Effective Internal Optimal Nicvax Dose Schedule Identified Smoking Cessation Long-term
Option Exercises Stock Vested 2006 Option Exercises Stock Vested 2007
Option Exercises Stock Vested 2008 Option Sar Grants Last
Options Orphan Drug Act
Orphan Medicinal Product Designation Other Biopharmaceutical Product Revenues
Other Biopharmaceutical Revenues Other Events
Other Income Expenses Net Includes Gained Repurchase Convertible Other Income Tax Disclosures
Other Information Other Matters
Other Restrictions Diligence Obligation Other Stock-based Awards
Other Vesting Provisions Performance Award Outlook 2005
Overall Health Benefit High Antibody Responders Smoked Fewer Overview
Ownership Data Pmas Regulatory Approvals Etc Page
Park Commerce Boulevard Parking Map
Part Part Other Information
Participants Solicitation Participation Espp
Patent Rights Trademarks Patents Proprietary Rights
Patents Proprietary Rights Not Provide Sufficient Protection Other Payment Purchase Price
Payment Terms Pentastaph
Pentastaph Development Status Pentavalent Staphvax Development Status
Performance Goals Weighting Award Performance Shares Units
Pfizer Phase Iib Study
Phase Iib Trial Data Phase Study
Philip Broenniman Visium Asset Management Phoslo
Phoslo Calcium Acetate Phoslo Revenues
Pivotal Registration Studies Development Plan Diligence Plan Commercialize Staphvax Not Successful
Plans Commercialize Nabi-hb Intravenous Hebig Phoslo Not Successful Plans Commercialize Nabi-hb Intravenous Phoslo Not Successful
Plans License Commercialize Hebig Not Successful Post-approval Regulation
Post-closing Covenants Potential Limitations Third-party Reimbursement Complex Regulations Products Other
Potential Limitations Third-party Reimbursement Other Pricing-related Matters Reduce Pre-closing Covenants
Preferred Stock Principal Accountants Fees Services
Principal Accounting Fees Services Prior Equity Plans
Pro Forma Information Sfas 123 2005 Pro Forma Information Sfas 123 Periods Prior 2006
Procedure Direct Claims Procedure Third-party Claims
Produce Hazardous Materials Claims Relating Improper Handling Storage Product Acquisitions
Product Candidates Undergo Clinical Trials Results Not Favorable Product Development Relationships
Product Specific Reimbursement Expectations Products Development
Program Materials Program Performance
Prometic Properties
Property Equipment Property Plant Equipment
Property Plant Equipment Depreciation Proposed 2007 Omnibus Incentive Plan
Proposed Amendment Restatement Espp Provisions
Proxy Card Valid Only Signed Dated Proxy Statement
Public Health Services National Institutes Purchase Price
Purchase Price Closing Purchase Sale Plasma
Purpose Quantitative Qualitative Disclosures Market Risk
Quantity Source Plasma Quarterly Period 2007
Ratification Appointment Independent Registered Public Accounting Firm Ratio Earnings Fixed Charges
Recent Accomplishments Recent Accomplishments Support Strategic Goals
Recent Events Recently Adopted Accounting Pronouncements
Recitals Reconciliation Revenue
Record Biopharmaceutical Revenues Drive Doubling Investment Staphvax Product Reduction Availability Specialty Antibodies Adversely Affect Ability Manufacture
Registrants Name Former Address Change Since Last Report Registrants Telephone Number Including Area Code
Registrants Telephone Number Including Area Code 301 770-3099 Regulation Disclosure
Reimbursement Related Party Transactions
Release Date 2007 Financial Results Relocation Sign-on Bonus Repayment Agreement
Remedies Cumulative Waiver Report Independent Registered Public Accounting Firm
Reports Payments Representations Warranties
Representations Warranties Buyer Representations Warranties Buyer Parent
Representations Warranties Covenants Repurchase Inventory
Research Development Expense Research Development Programs
Residual Activities Resignation Chief Executive Officer
Resignation Chief Financial Officer Resignation Henrik Rasmussen Phd Senior Vice President Clinical
Resignation Thomas Mclain Chairman Chief Executive Officer President Restated Compared 2002
Restatement Prior Financial Statements Restatement Related Intra-period Income Tax Allocations
Restricted Stock Results Operations
Results Operations 2009 2008 Results Operations Financial Condition
Results Special Meeting Shareholders Retention Program
Retirement Savings Plan Retiring Director
Retrospective Application Fsp Apb 14-1 Prior Period Consolidated Retrospective Application New Accounting Guidance Related Convertible Senior
Revenues Increased Cash Used Operating Activities Decreased Review Approval Ratification Transactions Related Persons
Review Operations Review Segment Performance
Richard Casper Investments Richard Manfori Analyst
Richard Mansouri Dellacamera Capital Managemen Richard Mansouri Dellacamera Capital Management
Right Negotiation Right Negotiation Refusal Agreement
Right Notice Transfer Right Refusal
Risk Factors Robert Chapman- Chapman Capital-analyst
Rockville 20852 Roxane Proceeding
Rules Regulations Safety Trends Continue Nicvax Shows Compensatory Smoking Increased
Sales Nabi-hb Directly Related Patient Treatment Protocols Number Sales Nabi-hb Directly Related Patient Treatment Protocols Small
Sales Segment Sanjay Dhody Deutsche Bank
Schedule Amendment Schedule Antibody Response Nabi Host Conference Call Today
Schedule Valuation Qualifying Accounts Reserves Schedules
Schedules Exhibits Scope Work Orders Products
Securities Authorized Issuance Equity Compensation Plans Securities Exchange Act 1934
Security Ownership Certain Beneficial Owners Security Ownership Certain Beneficial Owners Management Related Stockholder
See Accompanying Notes Consolidated Financial Statements Segment Information Currently Operate Single Business New Accounting
Sell Products Small Number Customers Loss Major Customer Seller Transition Assistance
Sellers Agreement Indemnify Separate Copies Beneficial Holders
Separation Agreement Johnson Seth Hamot Rrh Capital
Settlement Agreement Severance
Share-based Compensation Shareholder Communication Policy
Shareholders Rights Plan Shares Common Stock
Shares Issued Directors Shelf Registration Statement
Shipping Risk Loss Inspection Signature
Signature Page Follows Signatures
Significant Progress Advancing Key Strategic Objectives Signing Letter Agreement Below Optionee Hereby Acknowledges Agrees
Singing Letter Agreement Below Optionee Hereby Acknowledges Agrees Smoking Cessation
Solicitation Proxies Special Protocol Assessment Spa
Special Transaction Bonus Change Control Severance Payments Specialty Antibodies
Specific Obligations Standing Committees Board
Staphvax Staphvax Altastaph
State Other Jurisdiction Incorporation Statement Agreement
Stock Appreciation Rights Stock Based Compensation
Stock Option Grant Stock Option Restricted Grant
Stock Options Stock Purchase Plan
Stock Transfer Power Stock Units
Stockholder Proposals Next Annual Meeting Stockholders Equity
Strategic Alliances Strategic Alliances Licenses Royalty Agreements
Strategic Alternatives Process Not Successful Strategic Goal Review
Strategic Initiatives Strategic Initiatives Advance
Strategic Partnerships Commercial Alliances Strategic Plan
Strategic Priority Building Value Through Partnerships Alliances Securing Strategic Priority Optimizing Value Operations Leveraging Commercial Manufacturing
Strategic Transactions Strategy
Subcontractors Subject Costly Damaging Liability Claims Relating Antibody Contamination
Subject Costly Damaging Product Liability Other Claims Connection Submission Matters Vote Security Holders
Subsequent Event Subsequent Events
Successful Attract Retain Motivate Key Employees Inability Seriously Summary Vip Management Incentive Plan
Supplemental Cash Flow Information Supplemental Fair Value Disclosures
Supplemental Information Supply Manufacturing
Survival Representations Table Contents
Talecris Biotheraputics Tax Expense
Tax Information Tenants Personal Property
Term Expiration Termination Term Termination
Termination Termination Agreement
Termination Death Disability Employment Period Termination Employment
Termination Material Definitive Agreement Termination Survival
Termination Without Cause Employment Period Terms Awards
Terry Corcoran Lions Gate Capital Tony Campbell- Knott Partners-analyst
Total Transaction Value Trade Accounts Receivable
Trade Secrets Trademarks Trademark License
Transactions Related Persons Transition Period
Transition Services Agreement Treasury Stock
Treasury Stock Convertible Senior Notes Unable Expand Sales Marketing Capabilities Future Enter Maintain
Unable Pass Through Certain Cost Increases Antibody Product Uncertain Income Tax Positions
United States University Maryland Baltimore County
Unregistered Sale Equity Securities Unregistered Sales Equity Securities Proceeds
Unresolved Staff Comments Upcoming Milestones
Upcoming Milestones Product Pipeline Programs Valuation Expense Information Sfas 123r
Vern Passey Private Investor Via Facsimile Overnight Delivery
Vip Management Incentive Plan Vote Required
Voting Annual Meeting Warrants
Warranty Disclaimer Wilkins Avenue Rockville 20852
Winrho Sdf Other Biopharmaceutical Products Withdrawal
Wormser Kiely Galef Jacobs Llp 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki